Skip to main content Skip to section navigation Skip to footer
Avalo Therapeutics, Inc. IR Overview
  • Overview
  • News, events & presentations
    • Press Releases
    • Events
    • Presentations
    • Email alerts
  • Analyst coverage
  • Stock data
    • Quote and chart
    • Historical data
  • SEC filings
    • SEC filings overview
    • All SEC filings
    • Annual reports
    • Quarterly reports
    • Section 16 filings
  • Corporate governance
    • Board Committees & Governance Documents
    • Board of directors
  • IR resources
    • Contacts
    • FAQ
Avalo Therapeutics, Inc. Corporate Home
  • About
    • Overview
    • Leadership
    • Board of directors
    • Contact
  • Science
    • Overview
    • IL-1β in HS
    • IL-1β in CPPD
  • Pipeline
    • Overview
    • AVTX-009 for HS
    • AVTX-009 for CPPD
  • Patients
    • Our commitment
    • Clinical trials
    • Resources
    • Access to investigational therapies
  • Investors
    • Overview
    • News, events & presentations
    • Analyst coverage
    • Stock data
    • SEC filings
    • Corporate governance
    • IR resources
  • Careers
    • Overview
    • Values
    • Benefits
    • Job openings

Press Releases

News, events & presentations

News, events & presentations

  • Press Releases
  • Events
  • Presentations
  • Email alerts
Sep 6, 2023 7:00 am EDT
Avalo to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Aug 3, 2023 7:00 am EDT
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
Jul 6, 2023 4:01 pm EDT
Avalo to Participate in SVB Securities Therapeutics Forum
Jun 26, 2023 7:00 am EDT
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
Jun 1, 2023 7:00 am EDT
Avalo to Present at the Jefferies Healthcare Conference
May 22, 2023 7:00 am EDT
Avalo Announces Appointment of Michael Croft, Ph.D. and Jeff Edelson, M.D. to its Scientific Advisory Board
May 15, 2023 7:00 am EDT
Avalo to Present at ATS 2023 Respiratory Innovation Summit
May 10, 2023 7:00 am EDT
Avalo to Present at the 2023 RBC Capital Markets Global Healthcare Conference
May 4, 2023 4:01 pm EDT
Avalo Reports First Quarter 2023 Financial Results and Provides Business Updates
Mar 29, 2023 7:30 am EDT
Avalo Reports 2022 Financial Results and Provides Business Updates
  • Previous Pagearrow_back
  • Page 1
  • Page 2
  • Page 3
  • Page 4
  • Page 5
  • Page 6
  • Page 7
  • Page 8
  • Page 9
  • Page 10
  • …
  • Page 21
  • Next Pagearrow_forward
  • Contact IR
  • RSS
  • Email Alerts
  • Accessibility
    accessibility
410.522.8707
in
1500 Liberty Ridge Drive
Suite 321
Wayne, PA 19087
Avalo
PRIVACY POLICY DISCLAIMER
©2025 Avalo Therapeutics, Inc.